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Over the last two decades significant
research efforts and resources have been
devoted to identifying mycobacterial
proteins of value to diagnostic assays
and vaccine formulations. These scien-
tific endeavors were often preceded by first
identifying a target population of proteins,
for example cytoplasmic, cell envelope,
or extracellular. However, many of these
endeavors have overlooked the posttrans-
lational modifications (PTM) to which
these protein subsets may be targets of.
Consequently, we may be missing essen-
tial molecular information relevant to the
function and antigenicity of these effector
molecules, and in turn the pathobiology
of these bugs. Moreover, heterologous
expression of mycobacterial proteins in
hosts lacking homologous PTM systems
negates any functional and/or antigenic
role the PTM may impart. Functional and
pathogenic roles of PTMs, such as protein
glycosylation, have been reported for other
Gram-positive bacteria, especially in ref-
erence to mucosal pathogens (reviewed by
Szymanski and Wren, 2005). Our objec-
tive in this piece is to shed light on the
lack of PTM studies so that current and
future researchers hunting for diagnostic
and vaccine candidates shall: (i) be made
aware of PTMs of mycobacterial proteins,
and (ii) come to understand their growing
importance to both pathobiology and
Abbreviations: LC, liquid chromatography; MS,
mass spectrometry; MHC, major histocompatibility
complex; TCR, T-cell receptor; BCR, B-cell receptor;
BCG, Bacillus Calmette-Guérin; PPD, purified pro-
tein derivative; PBMC, peripheral bloodmononuclear
cell; MR, mannose receptor; DC-SIGN, dendritic cell-
specific intercellular adhesion molecule-3-grabbing
non-integrin.
immunogenicity. Interestingly, the last 5
years has only yielded 2 reports on the
global analyses of mycobacterial glycopro-
teins, both for M. tuberculosis (Mtb), and
over the last decade only a few studies
demonstrated the importance of PTMs
to the pathobiology and antigenicity of
select proteins in Mtb, M. bovis, and
Mycobacterium avium subsp. paratubercu-
losis (MAP). In this communication we
present the opinion that in a world of
cross-reactive epitopes, and high amino
acid sequence similarity between M. bovis,
MAP, and their saprophytic counterparts,
PTM diversity amongst these species may
confer a new level of epitope-specificity for
select antigens. We will also highlight that
in the case of protein glycosylation, the
type and extent of glycosyl moieties should
not been seen as having the same outcome.
Furthermore, the presence or absence of
the PTM of proteins included in subunit
vaccine formulations or attenuated strains,
may enhance or mask the processing, pre-
sentation, and immunogenicity of relevant
epitopes. Collectively, these data call to
action critical analyses of the components
we use to formulate mycobacterial vac-
cines. As the vast majority of PTM studies
have focused on glycosylation, this PTM
will be the focal point of discussion.
HISTORY OF MYCOBACTERIAL
GLYCOPROTEINS
Espitia and Mancilla (1989) first identi-
fied 3 glycoproteins in Mtb H37Rv cul-
ture filtrate (CF) using mannose-binding
lectin Concanavalin A. Immunoblotting
revealed 2 of the glycoproteins (Rv1860-
Apa, Rv0934) were reactive with 38% of
serum samples from active TB patients
tested; no reactivity was detected with
healthy control samples. Subsequent stud-
ies mapped the glycosylated peptides of the
Mtb Apa adhesin protein using endopep-
tidase digestion and MS analysis (Dobos
et al., 1995). Horn et al. (1999) exam-
ined the antigenicity of the Apa protein
in M. bovis BCG-immunized guinea pigs.
Using MS, they demonstrated mannosyla-
tion of native Apa purified from Mtb and
M.bovis, mannosylation of recombinantly
expressed Apa in M.smegmatis, however
with 2–3 additional mannose residues per
branch, and the lack of mannosylation of
recombinant E.coli Apa. In T-cell assays,
native Mtb and M. bovis Apa protein
elicited similar levels of lymphoprolifer-
ation, whereas recombinant E.coli Apa
showed negligible activity. Interestingly,
recombinant M. smegmatis Apa lympho-
proliferation was 10-fold less despite simi-
lar, albeit increased, glycosylation patterns
as the native proteins. This report was
the first to demonstrate that mycobacterial
proteins stimulate more robust immuno-
logical responses as glycoconjugates, and
that species-specific differences in glycosy-
lation alter this response. Interestingly, gly-
cosylation differences for Apa of Mtb and
M.marinum have also been demonstrated,
however, the functional implication of this
is yet to be elucidated (Coddeville et al.,
2012). To date, no follow up studies have
addressed, (i) differential mannosylation
in M. smegmatis, M. bovis, and Mtb, and
(ii) why variation in glycosylation results
in an altered immunological response.
Recently two complimentary
approaches, Con A lectin affinity chro-
matography, and MS analysis for O-linked
hexosylation, were taken to address
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global protein glycosylation in Mtb CF.
Interestingly, the MS analyses identified 13
glycoproteins in Mtb CF in contrast to the
41 captured by affinity chromatography
(González-Zamorano et al., 2009; Smith
et al., 2014). Liu et al. (2013) first linked
a functional and virulent role to the Mtb
mannosyl transferase membrane protein
(Rv1002c) by establishing a Rv1002c
mutant. Murine alveolar macrophages
co-cultured with the Rv1002c mutants
showed a 50% reduction in uptake over
H37Rv. Moreover, median survival of
SCID mice challenged with the Rv1002c
mutants increased by 41 days over H37Rv.
Collectively, these data highlight the sig-
nificant contribution of glycoproteins
to infectivity and virulence of Mtb. In
another study, MS mapping of the M.bovis
glycoprotein MPB83 identified a unique
mannose linkage not previously reported
inMtb glycoproteins (Michell et al., 2003).
These data raise interesting questions such
as: (i) how this linkage may affect interac-
tions with immunological receptors such
as the TCR, MHC, and/or BCR by enhanc-
ing/masking/modulating its binding, and
(ii) whether these linkages are part of the
antigenic determinant, and if so, do they
impart species-specificity even in highly
homologous proteins.
GLYCOSYLATION AND ANTIGENICITY
Glycosylation-dependent peptide epi-
topes were demonstrated by ELISA using
mannosidase-treated recombinant Mtb
Apa expressed in Streptomyces (Lara
et al., 2004). Reactivity of serum from
TB patients was significantly reduced after
Apa was treated with mannosidase. In
our lab, similar observations were found
with 17 MAP CF glycoproteins purified
by Con A lectin-affinity chromatography.
Both bovine and ovine paratuberculosis
serum contained antibodies against these
antigens. However, only bovine serum
activity was abrogated after mannosidase
treatment of these antigens (Mutharia
et al., 1997). Currently, our lab is identi-
fying these, and other MAP glycoproteins,
among the complement of secreted pro-
teins we recently identified (Facciuolo
et al., 2013). Using Con A lectin blotting
on MAP CF proteins concentrated and
resolved by RPLC we can reproducibly
detect 14 reactive bands by SDS-PAGE in
the range of 10–75 kDa (Facciuolo and
Mutharia, unpublished). Applying Con A
lectin-affinity chromatography 9 unique
bands were eluted, and resolved by SDS-
PAGE. By 2D PAGE, 6 of these 9 unique
bands have horizontal spot series (on
average 3 spots) indicative of PTMs. To
our knowledge, this is the most extensive
reporting on MAP glycoproteins.
Recently, protein glycosylation on
T-cell antigenicity and vaccination was
elucidated using native and recom-
binant Apa-protein isoforms of Mtb
(Nandakumar et al., 2013). In BCG+
PPD+ individuals, CD4+ cytokine-
secreting cells were significantly higher in
PBMCs stimulated with the native protein
than the recombinant isoform. Moreover,
the native glycosylated Apa uptake was
higher than that of the unglycosylated
recombinant isoform in dendritic cells
from PBMCs of both BCG+ and BCG−
individuals. In vitro analyses showed only
the glycosylated isoform bound recom-
binant human innate immune receptors
such MR, DC-SIGN, and DC-SIGNR.
Despite these significant differences, both
protein isoforms were equally protective
in BALB/c mice as subunit vaccines stim-
ulating similar CD4+ cytokine and serum
antibodies responses. These data suggest
that glycosylation is necessary for anti-
genicity, but not induction of protective
immunity. The outcomes of these data
are quite interesting when also consid-
ering the earlier studies by Ishioka et al.
(1992). Using synthetic peptides, three
GlcNAc-position-dependent outcomes
were observed in BALB/c immunized
mice. Positioning of the GlcNAc con-
jugated amino acid could either limit
lymphoproliferative responses to the gly-
cosylated peptide only, abolish antigenicity
of the peptide, or result in antigenicity of
both the glycosylated and unglycosylated
peptide isoforms. The authors speculated
that the consequences were the result of
MHC-TCR interactions where the glyco-
conjugate: is the antigenic determinant,
interfered with the MHC binding site,
or was distal of the critical MHC bind-
ing pocket, respectively. In light of these
data, careful analyses and consideration
of both glycosylation status and their site
of attachment on proteins are needed to
ensure the efficacy of these molecules
in stimulating the desired immuno-
logical response. These considerations
should also be applied in the development
of attenuated strains as the presence
or absence of glycosylated proteins
may either enhance/mask protective
stimulators/inducers of innate/adaptive
immunity.
The complexity of glycosylation in
addition to the consequences it carries
calls to action a bottom-up approach in
screening for novel vaccine candidates.
The potential of these effector molecules
to contain species-specific glycosylation
markers may benefit vaccine formulations,
in addition to diagnostic assays. The tech-
nical hurdles in obtaining the necessary
quantity and fidelity of glycoproteins from
slower growing Mycobacterium currently
presents the greatest challenge in this field,
but has had some measure of success via
heterologous expression, or native purifi-
cation by lectin-affinity purification cou-
pled with LC. These technical challenges
might best be served by efforts to glyco-
engineer PTM systems in faster growing
species. The sum of these data may aid
in identifying those effector molecules, (i)
that exclusively require their PTM for anti-
genicity, (ii) where the PTM is dispensable
for protective immunity, and (iii) contain-
ing new subsets of protective or relevant
antigens that had been masked by the
presence of a PTM.
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